Residency · Residency · Endocrinology

Osteoporosis - Evaluation and Treatment

Definition and Epidemiology

Definitions

Osteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to fracture. The WHO defines osteoporosis densitometrically as a T-score of -2.5 or below at the lumbar spine, total hip, or femoral neck on DXA. Clinical osteoporosis is diagnosed when a low-trauma (fragility) fracture occurs at the hip, spine, or other characteristic sites, regardless of the DXA T-score. Osteopenia, defined as a T-score between -1.0 and -2.5, represents increased risk that is lower than that conferred by osteoporosis on an individual basis, yet this group generates the majority of fragility fractures in the population because it encompasses a much larger number of individuals.

Epidemiology

Osteoporosis affects approximately 200 million people worldwide, with roughly 10 million diagnosed cases in the United States and an additional 54 million with low bone mass. The lifetime fracture risk is substantial: 50% for women and 20% for men over age 50. Hip fractures, numbering approximately 300,000 per year in the US, carry devastating consequences including 20-30% one-year mortality and loss of full mobility in 50% of survivors. Vertebral fractures are the most common osteoporotic fracture type, yet only 25-30% are clinically recognized. Their significance is amplified by the cascade effect: a single vertebral fracture increases the risk of subsequent vertebral fracture 5-fold within one year, underscoring the urgency of treatment initiation.

Pathophysiology

Peak Bone Mass and Age-Related Loss

Peak bone mass is achieved by age 25-30 and is determined primarily by genetics (60-80%), with additional contributions from nutrition, physical activity, and hormonal status. Age-related bone loss begins around age 40 and follows a characteristic pattern in women: an accelerated phase during the 5 years surrounding menopause (losing 2-3% per year), followed by a slower phase of 0.5-1% per year. Trabecular bone, predominant in the vertebrae and distal radius, is lost earlier and more rapidly than cortical bone, which predominates at the hip and radius shaft.

Estrogen Deficiency (Postmenopausal Osteoporosis)

The pathophysiology of postmenopausal osteoporosis centers on the loss of estrogen's protective effects on bone. Estrogen normally suppresses osteoclast activity through multiple mechanisms: reducing RANKL expression, increasing OPG production, and promoting osteoclast apoptosis. Estrogen withdrawal produces increased bone resorption markers (CTX, NTX) with resorption exceeding formation, resulting in net bone loss. Additionally, estrogen withdrawal increases RANKL expression by osteocytes and T-cells and elevates pro-inflammatory cytokines including IL-1, IL-6, and TNF-alpha that further stimulate osteoclastogenesis.

Secondary Causes of Osteoporosis

A thorough evaluation for secondary causes is essential in all patients with osteoporosis. Glucocorticoid therapy is the most common medication-related cause, with prednisone at 5 mg/day or greater for 3 months or more conferring significant risk. Endocrine causes include hyperparathyroidism, hyperthyroidism, Cushing syndrome, hypogonadism, type 1 diabetes, and growth hormone deficiency. Gastrointestinal conditions such as celiac disease, inflammatory bowel disease, bariatric surgery, and liver disease impair calcium and vitamin D absorption. Rheumatic diseases, particularly rheumatoid arthritis and ankylosing spondylitis, increase risk through both inflammation and glucocorticoid therapy. Hematologic conditions including multiple myeloma, mastocytosis, and thalassemia must be considered. Numerous medications beyond glucocorticoids contribute to bone loss, including aromatase inhibitors, GnRH agonists, anticonvulsants, chronic PPIs, heparin, SSRIs, and thiazolidinediones. Additional risk factors include COPD, CKD, organ transplantation, HIV, immobilization, alcoholism, and smoking.

Evaluation

DXA (Dual-Energy X-Ray Absorptiometry)

DXA is the gold standard for bone density measurement, providing areal BMD (g/cm2) at the lumbar spine (L1-L4), total hip, and femoral neck. The T-score, expressing standard deviations from the young adult mean, is used for postmenopausal women and men aged 50 or older. The Z-score, comparing to age-matched means, is appropriate for premenopausal women and men under 50, where a Z-score of -2.0 or below is defined as "below expected range for age." Clinicians must be aware of artifacts that can falsely elevate lumbar spine BMD, including degenerative changes, aortic calcification, vertebral compression fractures, and spinal hardware. The distal one-third radius measurement is reserved for specific scenarios: hyperparathyroidism (which preferentially affects cortical bone), obesity exceeding the DXA table weight limit, and bilateral hip replacements.

Trabecular bone score (TBS) is a texture analysis derived from DXA that reflects bone microarchitecture and supplements BMD information. A low TBS, even in the setting of normal BMD, indicates increased fracture risk. TBS is particularly valuable in glucocorticoid-induced osteoporosis and type 2 diabetes, conditions in which BMD characteristically underestimates fracture risk.

FRAX (Fracture Risk Assessment Tool)

FRAX is a WHO-validated algorithm that predicts the 10-year probability of major osteoporotic fracture (MOF) and hip fracture. Input variables include age, sex, BMI, prior fracture, parent hip fracture, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, alcohol intake (3 or more units daily), smoking, and femoral neck BMD (optional). The National Osteoporosis Foundation recommends treatment when the 10-year MOF risk reaches 20% or greater or the hip fracture risk reaches 3% or greater. FRAX has recognized limitations: it underestimates risk in patients with recent fractures, diabetes, or dose-dependent glucocorticoid effects and falls, and it does not incorporate lumbar spine BMD.

Laboratory Evaluation for Secondary Causes

A comprehensive laboratory evaluation should include CBC, comprehensive metabolic panel (calcium, phosphate, creatinine, albumin, alkaline phosphatase), 25(OH)D, PTH, and TSH. Additional tests to consider based on clinical suspicion include serum protein electrophoresis and free light chains (myeloma), celiac serology (tissue transglutaminase IgA), 24-hour urine calcium and creatinine, testosterone (in males), cortisol (if Cushing is suspected), and tryptase (mastocytosis). Bone turnover markers -- P1NP for formation and CTX for resorption -- are useful for monitoring therapeutic response but not for diagnosis.

Vertebral Fracture Assessment (VFA)

VFA is a DXA-based lateral spine imaging technique (T4-L4) that identifies prevalent vertebral fractures. Because many vertebral fractures are asymptomatic, their identification fundamentally changes management by establishing clinical osteoporosis regardless of T-score. VFA is indicated when the T-score is below -1.0 with age 70 or greater (women) or 80 or greater (men), when the T-score is -1.5 or below with specific risk factors, or when historical height loss exceeds 1.5 inches.

<image>A diagnostic workup flowchart for osteoporosis. Start with screening criteria: postmenopausal women ≥65, men ≥70, younger adults with risk factors. Step 1: DXA scan at spine and hip. Show T-score interpretation: normal (>-1.0), osteopenia (-1.0 to -2.5), osteoporosis (≤-2.5). Step 2: For osteopenia, calculate FRAX score. If FRAX ≥20% MOF or ≥3% hip → treat. If below threshold → reassess in 2-3 years. Step 3: For all osteoporosis diagnoses → secondary cause evaluation (laboratory panel shown). Step 4: VFA in appropriate candidates. Step 5: Clinical osteoporosis diagnosis if fragility fracture regardless of DXA. Include a side panel listing all secondary causes to evaluate. Use clinical algorithm format with decision nodes.</image>

Pharmacologic Treatment

Antiresorptive Agents

Bisphosphonates (First-Line for Most Patients)

Bisphosphonates bind to hydroxyapatite in bone and are internalized by osteoclasts during bone resorption, where they inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, leading to osteoclast apoptosis. Alendronate at 70 mg orally weekly reduces vertebral fractures by 47% and hip fractures by 51% (FIT trial). Risedronate at 35 mg orally weekly reduces both vertebral and non-vertebral fractures (VERT and HIP trials). Ibandronate at 150 mg orally monthly or 3 mg IV quarterly reduces only vertebral fractures without proven hip fracture reduction, making it less preferred. Zoledronic acid at 5 mg IV annually reduces vertebral fractures by 70% and hip fractures by 41% (HORIZON trial) and offers the simplest adherence profile. The HORIZON Recurrent Fracture Trial also demonstrated a 28% reduction in mortality after hip fracture.

Oral bisphosphonates require careful administration on an empty stomach with 6-8 ounces of water, remaining upright for 30-60 minutes, with no food or drink for 30-60 minutes. They are contraindicated when eGFR falls below 30-35 mL/min, in esophageal disorders (for oral forms), with uncorrected hypocalcemia, or with current jaw surgery. Side effects include gastrointestinal effects (esophagitis, ulcers with oral forms), acute phase reactions (fever, myalgias lasting 24-48 hours after IV zoledronic acid, reduced with acetaminophen pretreatment), and hypocalcemia (particularly with vitamin D deficiency). Rare but serious adverse effects include osteonecrosis of the jaw (ONJ, approximately 1:10,000 to 1:100,000 at osteoporosis doses, much higher at oncologic doses) and atypical femoral fractures (AFF, stress fractures in the subtrochanteric or diaphyseal femur associated with use beyond 5 years, presenting with prodromal thigh pain, with bilateral X-rays recommended).

Denosumab (Prolia)

Denosumab is a fully human monoclonal antibody against RANKL that inhibits osteoclast differentiation and activation. Dosed at 60 mg subcutaneously every 6 months, it reduces vertebral fractures by 68%, hip fractures by 40%, and non-vertebral fractures by 20% (FREEDOM trial). Its advantages include independence from renal clearance (usable in CKD) and continuous BMD gains over 10 years without the plateau characteristic of bisphosphonates.

However, the critical discontinuation risk of denosumab cannot be overemphasized. Rapid bone loss and vertebral fracture rebound occur within 6-12 months of stopping the drug, with up to 7% of patients developing multiple vertebral fractures. Transition to a bisphosphonate before or after discontinuing denosumab is mandatory; zoledronic acid should be given 6 months after the last denosumab dose when bone turnover markers begin rising. Side effects include skin infections (cellulitis, eczema), hypocalcemia (particularly in CKD, requiring calcium and vitamin D repletion), ONJ (at similar risk to bisphosphonates at osteoporosis doses), and AFF (very rare).

Anabolic Agents

Teriparatide (Forteo) - PTH(1-34)

Teriparatide harnesses the anabolic effect of intermittent PTH(1-34) exposure, which stimulates osteoblast activity more than osteoclast activity, producing net bone formation during an "anabolic window." Dosed at 20 mcg subcutaneously daily for up to 2 years, it reduces vertebral fractures by 65% and non-vertebral fractures by 35%, with BMD gains of 10-13% at the spine and 3-6% at the hip. Treatment must be followed by antiresorptive therapy to maintain gains. Side effects include orthostatic hypotension, leg cramps, nausea, and mild hypercalcemia (11%). Contraindications include pre-existing hypercalcemia, Paget disease, unexplained elevated alkaline phosphatase, prior radiation to the skeleton, open epiphyses, and bone metastases. The osteosarcoma risk observed in rodent data has not been confirmed in over 15 years of post-marketing surveillance.

Abaloparatide (Tymlos) - PTHrP(1-34) Analog

Abaloparatide is a PTH1R agonist that preferentially binds the RG receptor conformation, producing potent anabolic effects with less stimulation of bone resorption than teriparatide. At 80 mcg subcutaneously daily for up to 2 years, the ACTIVE trial demonstrated 86% reduction in vertebral fractures and 43% reduction in non-vertebral fractures, with a numerical reduction in hip fractures. BMD gains, particularly at the hip, may be slightly greater than with teriparatide (ACTIVExtend trial). It carries the same osteosarcoma boxed warning and similar contraindications as teriparatide.

Romosozumab (Evenity) - Anti-Sclerostin Antibody

Romosozumab binds and neutralizes sclerostin, disinhibiting the Wnt signaling pathway and producing a unique "dual effect" of simultaneously increasing bone formation and decreasing bone resorption. Dosed at 210 mg subcutaneously monthly (two 105 mg injections) for 12 months only, it reduces vertebral fractures by 73% and clinical fractures by 36% (FRAME trial) and proved superior to alendronate in the ARCH trial (48% lower vertebral fractures). It produces the largest BMD gains of any osteoporosis therapy: 13-15% at the spine and 6-7% at the hip at 12 months.

A cardiovascular safety signal identified in the ARCH trial showed a potential increase in cardiovascular events (romosozumab versus alendronate), resulting in a boxed warning for MI, stroke, and cardiovascular death. Romosozumab is contraindicated within 12 months of MI or stroke. Treatment is limited to 12 months because the anabolic effect wanes beyond this point, with bone formation markers returning to baseline. Antiresorptive consolidation with denosumab or a bisphosphonate must follow to maintain gains.

<image>A treatment sequencing diagram for osteoporosis showing optimal drug combinations over time. X-axis: time in years. Three treatment strategies shown as parallel timelines: Strategy 1 (Moderate risk): Bisphosphonate alone for 5 years → drug holiday assessment → resume or continue based on risk. Strategy 2 (High risk/severe osteoporosis): Anabolic first approach - teriparatide or abaloparatide for 2 years (show BMD rising steeply) → transition to denosumab or bisphosphonate (BMD maintained). Strategy 3 (Very high risk): Romosozumab for 12 months (show largest BMD gain) → denosumab (BMD continues to rise) → with plan for eventual bisphosphonate transition. Show BMD trajectory curves for each strategy on a graph overlay. Include a warning box about denosumab discontinuation requiring bisphosphonate bridge. Use timeline format with color-coded phases.</image>

Other Agents

Raloxifene (Evista), a selective estrogen receptor modulator, reduces vertebral fractures by 30-50% (MORE trial) but does not reduce hip fractures. It increases VTE risk, reduces breast cancer risk, and may cause hot flashes, limiting its current use for osteoporosis. Estrogen/HRT reduces all fractures (WHI demonstrated 34% hip fracture reduction) but is not considered first-line due to breast cancer, VTE, and cardiovascular risk; it may be considered in early postmenopausal women with vasomotor symptoms. Calcitonin nasal spray provides minimal fracture reduction (PROOF trial: 33% vertebral only) and is no longer recommended as first-line therapy, with concerns about a potential malignancy signal with chronic use.

Treatment Decision-Making

Who to Treat (NOF/AACE)

Pharmacologic treatment is recommended for postmenopausal women and men aged 50 or older with a hip or vertebral fracture, T-score of -2.5 or below, or T-score between -1.0 and -2.5 with FRAX showing 20% or greater MOF risk or 3% or greater hip fracture risk. Very high fracture risk, defined by recent fracture within 2 years, T-score of -3.0 or below, multiple fractures, fall risk, or FRAX exceeding 30%, warrants an anabolic-first treatment strategy.

Treatment Sequence Strategy

For standard-risk patients, oral bisphosphonate is first-line, with 5 years of alendronate or risedronate or 3 years of zoledronic acid followed by reassessment for a drug holiday. For high- and very-high-risk patients, anabolic therapy first with romosozumab for 12 months or teriparatide/abaloparatide for 2 years, followed by antiresorptive consolidation with denosumab or a bisphosphonate, is the recommended approach. The rationale for anabolic-first sequencing rests on evidence of greater BMD gains: the ARCH trial demonstrated that romosozumab followed by alendronate was superior to alendronate alone, and the VERO trial showed teriparatide superior to risedronate for fracture prevention in severe osteoporosis.

Bisphosphonate Drug Holiday

A drug holiday may be considered after 5 years of oral bisphosphonate or 3 years of IV zoledronic acid. Reassessment should include T-score (if above -2.5 at the hip), absence of recent fracture, and FRAX below the treatment threshold; if all criteria are met, a holiday of 1-3 years for oral agents or 3-5 years for zoledronic acid is reasonable. Monitoring during the holiday includes annual DXA and bone turnover markers, with rising CTX suggesting wearing off and prompting consideration of resuming therapy. The FLEX trial demonstrated that continuing alendronate beyond 5 years reduced clinical vertebral fractures in patients with T-scores of -2.5 or below or prevalent vertebral fractures. Drug holidays must never be undertaken with denosumab due to the risk of rebound vertebral fractures; transition to a bisphosphonate is always required first.

Glucocorticoid-Induced Osteoporosis (GIOP)

Risk

Fracture risk increases within 3-6 months of starting glucocorticoids, with vertebral fractures predominating. The risk is dose-dependent, with prednisone at 7.5 mg/day or more carrying the highest risk, though even 2.5-7.5 mg/day increases risk above baseline. Bone loss is maximal in the first 6-12 months and then continues at a slower rate with ongoing use. The unique pathophysiology of GIOP involves glucocorticoid suppression of osteoblast function (reduced bone formation) exceeding its stimulation of bone resorption. Glucocorticoids also reduce intestinal calcium absorption and increase renal calcium excretion.

ACR/AACE Guidelines

All patients receiving glucocorticoids should receive calcium 1000-1200 mg/day plus vitamin D 600-800 IU/day. Pharmacologic therapy is indicated when prednisone at 2.5 mg/day or more is anticipated for 3 months or longer in patients with moderate-to-high fracture risk (adjusted for glucocorticoid dose using FRAX). First-line agents include oral bisphosphonates (alendronate, risedronate), IV zoledronic acid, denosumab, and teriparatide. GIOP is the one clinical setting where anabolic therapy may be particularly advantageous, given the formation-dominant pathophysiology of glucocorticoid-induced bone loss.

Key Clinical Pearls

• The "anabolic-first" treatment strategy is now recommended for very high-risk patients; starting with romosozumab, teriparatide, or abaloparatide before transitioning to antiresorptive yields greater BMD gains and fracture prevention than starting with bisphosphonates
• Denosumab discontinuation causes rapid BMD loss and vertebral fracture rebound within 6-12 months; ALWAYS transition to a bisphosphonate (preferably zoledronic acid) when stopping denosumab
• Most osteoporotic fractures occur in patients with osteopenia (T-score -1.0 to -2.5), not osteoporosis, because this is a much larger population; FRAX helps identify which osteopenic patients warrant treatment
• Romosozumab has a cardiovascular safety signal; it is contraindicated within 12 months of MI or stroke; always assess cardiovascular risk before prescribing
• The imminent fracture risk after a first vertebral fracture is highest in the first 1-2 years (5x risk of subsequent fracture); this urgency supports rapid initiation of therapy, ideally anabolic, rather than a "watch and wait" approach
• Trabecular bone score (TBS) adds fracture risk information beyond BMD, particularly in conditions where BMD underestimates risk (type 2 diabetes, glucocorticoid use); incorporate TBS into FRAX when available

References

1. Eastell R, et al. "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2019;104(5):1595-1622.
2. Cosman F, et al. "Romosozumab Treatment in Postmenopausal Women with Osteoporosis (FRAME)." N Engl J Med. 2016;375(16):1532-1543.
3. Saag KG, et al. "Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis (ARCH)." N Engl J Med. 2017;377(15):1417-1427.
4. Shoback D, et al. "Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update." J Clin Endocrinol Metab. 2020;105(3):587-594.
5. Buckley L, et al. "2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis." Arthritis Rheumatol. 2017;69(8):1521-1537.

Read this lecture as Markdown